German biotechnology company BioNTech, which developed a covid-19 vaccine with Pfizer, posted a net profit of 3915.3 million euros as of June, recovering from a loss of 141.7 million euros a year earlier.
BioNTech today said its operating profit was 5860.6 million euros in the first half compared to a loss of 140.2 million euros in the same period in 2020.
And the value of sales rose to 7,356.9 million euros, 106 times what it was a year ago, when it reached 69.4 million euros, and this is due to the “rapid increase in the delivery of a vaccine against Covid-19 worldwide.”
“We and our partner, Pfizer, have passed the milestone of 1 billion doses of covid-19 vaccine shipped worldwide. We are very proud to have achieved this milestone in the presentation of the results,” said BioNTech CEO and Founder, Ugur Sahin, in presenting the results. Only six months.”
To combat the epidemic, Shaheen said, the vaccine supply has been increased to more than 100 countries and regions around the world and access to low- and middle-income countries has been facilitated.
BioNtech now expects the vaccine to be licensed in more regions and for more populations, and clinical trials are taking place in children aged six months to 11 years and in healthy pregnant women.
Meanwhile, BioNtech is working to develop treatments for cancer, having recently begun new clinical trials in two programs.
